The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
I agree Kevin. That indeed would be the norm. However there is a big political agenda with Trump’s re election campaign going on, that can’t be overlooked.
The prize of having Avacta packed up and shipped over there would potentially be massive. Given the content of his briefings I suspect his ego would explode and money is no object when attempting to secure re election on the back of a Covid solution.
I have watched his briefings in a state of utter dismay.
I hope the company’s UK future can be safeguarded.
I wonder if it’s a coincidence that Danaher had a 3.2b$ capital raise last week part of which is to be used for acquisitions.
My big concern is that if a big pharma buys us over they may pack the co up and ship it across to the US. The duck would love that!
This country needs to retain innovative companies like Avacta. We can’t afford to lose them or the fantastic expertise of the people that work there.
I’m a long term holder here and I’m pleased to have a real interest in the success of Avacta.
The company will grow and I believe Alistair Smith when he says that there will be long term share holder value.
That’s good enough for me.
Now now Mapp. No need for that!!! Actually I really like quite like her. I’m going to pick up her shares this morning!!
Also we won’t need pay heed to her again as she won’t be a holder.
I can’t comment on her fingers thankfully.
There will be many types of tests using different technologies and different techniques for collecting samples.
The Roche test will help determine who has had the virus. This will be useful in identifying the spread of the virus throughout society. Issues like who is most at risk and identifying hot spots etc
The Cytiva test will identify who actually has the virus and will identify who can still infect others, who needs to isolate or who can get on their flight.
So they both have their uses and the market is large enough to support lots of different tests and variations on the same theme.
So don’t clog up the board with “there’s competition to our test, look out, the share price will fall” none sense.
There will be competition of course there will.
The market is diverse and extensive enough for many different players.
So don’t panic Mannering.
Day trading is equivalent to betting on the horses. Yes of course you might occasionally get lucky but I’ve never seen a bookie on a bike and the MMs are the bookies in this instance. They have access to all the relevant information to stack the odds in their favour. They can see the orders that have come in during the night and early morning before the market opens They then set a price that gives them a buy/ sell option and creates their margin. That’s why I never trade in the first hour, rule number 1. They can see all the stop loss instructions and can shake the tree to clear them out when the time is right. As I say. You might get lucky but the best option is get on the right bus, hold on tight and enjoy the ride. Get off once you’re reached your destination.
The USA has done the most amazing “jab.”They have conducted twice as many tests as South Korea. No country in the world has the testing capacity or equipment that the US has. They are helping the rest of the world creating good will and saving lives.
China could even be trying to steal US technology.
What an amazing effort by everyone connected in developing new tests. New tests including antigen tests rely on point of test supplies ( millions of swans available ). 5000 machines to produce results at labs throughout the country and enough supplies to keep them operational.
They truly are amazing.
But then my mother always said self praise is no praise.
The FDA will expedite new test approvals. Probably good news for Avc. The current tests are all swab based. Potentially good news for AVC.
I’ve never watched a briefing from the US before.
Very enlightening and entirely depressing.
It won’t be running in both races that’s for sure. Not even Shergar could have done that. Perhaps we will let them have the National and we will go for the Derby. Two differ disciplines for two different horses. But our race has no fences to negotiate. Besides. I always back a sound jockey and my money is on Alistair Smith every time !
My belief is that today’s increase is about right. The news that the affimer reagents have been sent to Cyvita was expected by the market.
The potential for the “dual” aspect Is not well understood and some posters on here are merely guessing at the opportunities this creates. Some clarity around this directiy from Avacta may push the share price up again. A stress point of 121p has been identified previously and this has proven to be correct.
The next key milestones will be that Cytiva have successfully trialled the strip test In a format that can be mass produced quickly. Following which regulatory approval should see further rises. Steady sustainable growth in the share price although less exciting, is much more attractive to long term holders than volatile peaks and troughs.